Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS

Clinical Observation of Recombinant Human Growth Hormone Injection Assisted in Vitro Fertilization and Embryo Transfer (IVF-ET) in the Treatment of Polycystic Ovary Syndrome (PCOS)

Observe validity of Recombinant Human Growth Hormone Injection assisted in IVF-ET (in vitro fertilization and embryo transfer) treatment of PCOS (polycystic ovary syndrome) patients.

Inclusion Criteria:

• Age between 25 and 35 years old, married female and infertile.
• BMI≥25kg/m2.
• Diagnosed as PCOS.
• No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid, adrenal disease.
• Subjects do not take part in other clinical trial study within 3 months.
• The subjects sign the informed consent form.

Exclusion Criteria:

• BMI<25kg/m2.
• Hyperprolactinemia and congenital adrenal cortical hyperplasia.
• Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome.
• Pelvic and peritoneal tumor and tumor secreting hyperandrogenism.
• Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity.
• Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the serum of creatinine is 2 times higher than the normal level.
• Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma>4 cm, adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis of reproductive system.
• Allergic to E. coli. expression product and its excipients.
• Being involved in other drug clinical researchers.
• The researchers consider who is not suitable for the group.